Results 1 to 10 of about 272 (113)

Clinical Outcomes of MLC601 (NeuroAiD^TM) in Traumatic Brain Injury: A Pilot Study [PDF]

Brain Sciences, 2020
Background: MLC601 is a natural product formulation from Chinese medicine that is extensively studied in ischemic stroke. Traumatic brain injury (TBI) shares pathophysiological mechanisms with ischemic stroke, yet there are few studies on the use of ...
Asra Al Fauzi, Krisna Tsaniadi Prihastomo, I. G. M. Aswin R. Ranuh, Tedy Apriawan, Joni Wahyuhadi, M. Arifin Parenrengi, Agus Turchan, Abdul Hafid Bajamal, Hari Basuki Notobroto   +8 more
doaj   +15 more sources

Ischemic Stroke and Savings in Time to Achieve Functional Recovery: Experience from NeuroAiD [PDF]

Journal of Cardiovascular Development and Disease, 2023
Despite recent progress with revascularisation interventions after acute ischemic stroke, many patients remain disabled after stroke. Using data from a multi-centre, randomised, double-blind, placebo-controlled trial of a neuro-repair treatment (NeuroAiD/
Narayanaswamy Venketasubramanian, Yogesh Pokharkar, Christopher Chen   +2 more
exaly   +6 more sources

MLC601 in vascular dementia: an efficacy and safety pilot study [PDF]

Neuropsychiatric Disease and Treatment, 2017
Hossein Pakdaman,1 Ali Amini Harandi,1 Koroush Gharagozli,1 Mehdi Abbasi,1 Majid Ghaffarpour,2 Farzad Ashrafi,1 Hosein Delavar Kasmaei,1 Asghar Amini Harandi3 1Brain Mapping Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran ...
Pakdaman H, Amini Harandi A, Gharagozli K, Abbasi M, Ghaffarpour M, Ashrafi F, Delavar Kasmaei H, Amini Harandi A   +7 more
doaj   +7 more sources

The Use of NeuroAiD (MLC601) in Postischemic Stroke Patients. [PDF]

Rehabil Res Pract, 2012
Aim. We aimed to assess the efficacy of MLC601 on functional recovery in patients given MLC601 after an ischemic stroke. Methods. This is a retrospective cohort study comparing poststroke patients given open-label MLC601 (; 9 female) for three months and
Navarro JC, Molina MC, Baroque Ii AC, Lokin JK.   +3 more
europepmc   +7 more sources

The value of patient selection in demonstrating treatment effect in stroke recovery trials: lessons from the CHIMES study of MLC601 (NeuroAiD) [PDF]

Journal of Evidence-Based Medicine, 2015
© 2015 Chinese Cochrane Center, West China Hospital of Sichuan University and Wiley Publishing Asia Pty Ltd. Objective: The CHIMES Study compared MLC601 to placebo in patients with ischemic stroke of intermediate severity in the preceding 72 hours.
Narayanaswamy Venketasubramanian, Chun Fan Lee, Christopher Chen   +2 more
exaly   +11 more sources

Efficacy and Safety of MLC601 in the Treatment of Mild Cognitive Impairment: A Pilot, Randomized, Double-Blind, Placebo-Controlled Study [PDF]

Dementia and Geriatric Cognitive Disorders Extra, 2017
Background and Aim: Mild cognitive impairment (MCI) is characterized by declined cognitive function greater than that expected for a person’s age. The clinical significance of this condition is its possible progression to dementia.
Hossein Pakdaman, Ali Amini Harandi, Mehdi Abbasi, Hosein Delavar Kasmaei, Farzad Ashrafi, Koroush Gharagozli, Farhad Assarzadegan, Behdad Behnam, Mehran Arabahmadi   +8 more
doaj   +6 more sources

The Alzheimer's disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild‐to‐moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine—A randomized, double‐blind, placebo‐controlled trial [PDF]

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2019
Background Dementia is a large and growing health care burden globally, and its major cause is Alzheimer's disease (AD). MLC901 (Neuroaid II) is a simplified form of MLC601 (Neuroaid), a Traditional Chinese Medicine with neuroprotective and ...
Christopher L.H. Chen, Purabi Reang Sharma, Boon Yeow Tan, Casuarine Low, Narayanaswamy Venketasubramanian   +4 more
doaj   +3 more sources

Translational Medicine in Acute Ischemic Stroke and Traumatic Brain Injury—NeuroAiD Trials, from Traditional Beliefs to Evidence-Based Therapy [PDF]

Biomolecules
Acute ischemic stroke (AIS) and traumatic brain injury (TBI) are two severe neurological events, both being major causes of death and prolonged impairment.
Narayanaswamy Venketasubramanian, Tseng Tsai Yeo, Christopher Chen   +2 more
exaly   +4 more sources

The Efficacy and Safety of Ischemic Stroke Therapies: An Umbrella Review [PDF]

Frontiers in Pharmacology, 2022
Background: Ischemic stroke is a leading cause of morbidity and mortality in neurological diseases. Numerous studies have evaluated the efficacy and safety of ischemic stroke therapies, but clinical data were largely inconsistent.
Yongbiao Li, Ruyi Cui, Fangcheng Fan, Yangyang Lu, Yangwen Ai, Hua Liu, Shaobao Liu, Yang Du, Zhiping Qin, Wenjing Sun, Qianqian Yu, Qingshan Liu, Yong Cheng, Yong Cheng   +13 more
doaj   +2 more sources

NeuroAid II (MLC901) in Haemorrhagic Stroke [PDF]

Case Reports in Neurology, 2020
Stroke is a leading cause of death and disability. NeuroAid (MLC601), which originates from Traditional Chinese Medicine, comprises herbal and animal components, and has been shown to improve the functional status of patients after ischaemic stroke.
Chai-Hoon Nowel Tan, David Choy, Narayanaswamy Venketasubramanian   +2 more
doaj   +2 more sources